Aavocyte, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.

AAVogen, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.

A2 Biotherapeutics, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.

3SBio Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.

NCT07550465 clinical trial report covering QLS1410, Phase 2, endpoints, sponsor, geography, readout timing and development white space.

NCT07550517 clinical trial report covering Lutetium (177 Lu) Vipivotide Tetraxetan, Phase 2, endpoints, sponsor, geography, readout timing and development

NCT07551427 clinical trial report covering Rovadicitinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.

NCT07550855 clinical trial report covering Rituximab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.

NCT07550595 clinical trial report covering Oritavancin Diphosphate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.

NCT07549841 clinical trial report covering [68Ga]FAPI-46, Phase 2, endpoints, sponsor, geography, readout timing and development white space.

ChiCTR2600123414 clinical trial report covering Fluzoparib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.

NCT07551882 clinical trial report covering Oxytocin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.